TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06015906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plenum® Guide
Description: Plenum® Guide is a white, absorbable synthetic regenerative membrane composed of poly(dioxanone), which will be installed on the tooth extraction sockets.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plenum® Guide
Description: Plenum® Guide is a white, absorbable synthetic regenerative membrane composed of poly(dioxanone), which will be installed on the tooth extraction sockets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenum® Guide
Description: Plenum® Guide is a white, absorbable synthetic regenerative membrane composed of poly(dioxanone), which will be installed on the tooth extraction sockets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenum® Guide
Description: Plenum® Guide is a white, absorbable synthetic regenerative membrane composed of poly(dioxanone), which will be installed on the tooth extraction sockets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenum® Oss
Description: Plenum® Oss is a synthetic bone graft based on biphasic calcium phosphate, which will be used to fill the tooth extraction sockets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenum® Oss
Description: Plenum® Oss is a synthetic bone graft based on biphasic calcium phosphate, which will be used to fill the tooth extraction sockets.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: Tooth extraction and subsequent surgical procedure of guided bone regeneration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: Tooth extraction and subsequent surgical procedure of guided bone regeneration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Tooth extraction and subsequent surgical procedure of guided bone regeneration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Tooth extraction and subsequent surgical procedure of guided bone regeneration.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Tooth extraction
Description: Tooth extraction and subsequent surgical procedure of guided bone regeneration.
Study: NCT02897089

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhesive agent
Description: Agents used to bond the restorative materials to teeth structure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhesive agent
Description: Agents used to bond the restorative materials to teeth structure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhesive agent
Description: Agents used to bond the restorative materials to teeth structure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhesive agent
Description: Agents used to bond the restorative materials to teeth structure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhesive agent
Description: Agents used to bond the restorative materials to teeth structure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhesive agent
Description: Agents used to bond the restorative materials to teeth structure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Adhesive agent
Description: Agents used to bond the restorative materials to teeth structure.
Study: NCT06157528

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Patients were treated with abarelix prior to the examination
Study: NCT05070832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Hyperthermia
Description: Hyperthermia is a type of treatment in which tumor is heated to as high as 40.5-43℃ to help damage and kill cancer cells with little or no harm to normal tissue.
Study: NCT04648826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroEclipse II Breath Actuated Nebulizer
Description: Patients will receive AZA via commercial device, AeroEclipse II Breath Actuated Nebulizer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroEclipse II Breath Actuated Nebulizer
Description: Patients will receive AZA via commercial device, AeroEclipse II Breath Actuated Nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W \[once every 3 weeks\]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W \[once every 3 weeks\]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.
Study: NCT04777825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback training (Symbiocenter)
Description: 12 sessions of thirty minutes. Patients will participate through several serious game associated with HRV biofeedback training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation session
Description: Each patient will therefore be presented individually with a Powerpoint consisting of 35 slides divided into 4 sub-sections explaining in a fun and educational format the physiological model of stress, the respiratory function and its benefits, presentation of various relaxation techniques and recommendations for reading (stress management, letting go, mindfulness meditation) and other tools to help relaxation (smartphone applications).

Intervention type: OTHER
Group type: OTHER
Intervention: psychoeducation session
Description: Each patient will therefore be presented individually with a Powerpoint consisting of 35 slides divided into 4 sub-sections explaining in a fun and educational format the physiological model of stress, the respiratory function and its benefits, presentation of various relaxation techniques and recommendations for reading (stress management, letting go, mindfulness meditation) and other tools to help relaxation (smartphone applications).
Study: NCT05730998

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ANTHOCRAN FITOSOMA
Description: The product (Anthocran phytosome or placebo) will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
Study: NCT05780905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Auto-Injector
Description: Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist.~At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively.~The target dose for subjects is 1mg per week up to the 52 week treatment duration.
Study: NCT05987943

Intervention type: PROCEDURE
Group type: OTHER
Intervention: A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
Description: A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
Study: NCT05410704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Pelvic floor muscle exercises and diaphragmatic breathing exercise
Study: NCT04151901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Rehabilitation
Description: Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Rehabilitation
Description: Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking-based rehabilitation
Description: Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking-based rehabilitation
Description: Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
Study: NCT05780905

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05230745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ContraBand implants
Description: Percutaneous implantation of the ContraBand devices by right heart catheterization
Study: NCT06075043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Oral administration of AND017 capsules three times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Oral administration of AND017 capsules three times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Oral administration of AND017 capsules three times per week
Study: NCT05196477

Intervention type: DRUG
Intervention: Olokizumab
Description: The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).

Intervention type: DRUG
Intervention: Standard therapy
Description: Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.

Intervention type: DRUG
Intervention: Standard therapy
Description: Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
Study: NCT05143606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-printed airway simulator
Description: Two self-directed training on a standard fiberoptic bronchoscope and a custom-made 3D airway simulator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality software, AirwayEx
Description: Two self-directed training on AirwayEx. With additional training as necessary.
Study: NCT05531890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 medium dose fast Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 medium dose slow Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 high dose fast Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 high dose fast Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 high dose fast Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 low dose fast Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone solution as intramuscular injection Period 1 and Period 2
Description: reference product 0.1 mg/kg betamethasone solution as an intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Oral Solution Period 1 and Period 2
Description: Comparator product 0.1 mg/kg betamethasone oral drops solution
Study: NCT05553223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microdoses of activity
Description: Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
Study: NCT05153330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.
Study: NCT05580497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Wearable Robotic Knee System
Description: Power assistance will be provided from the motor to the knee joint
Study: NCT05803642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.
Study: NCT05549167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus 0,8 mg/m2, but \<2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
Study: NCT05277077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: The experimental group will follow a PNE protocol based on previous procedure for a whole period of 6 weeks in addition the conventional treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients from both groups will receive a conventional 6-week treatment programme (30 treatment sessions, five a week, for 90min duration).
Study: NCT04758052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of placement
Description: Simultaneous placement of tracheostomy and gastrostomy
Study: NCT04799847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
Study: NCT04731350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial extracorporeal shock wave
Description: Radial shock wave device, Swiss DolorClast (EMS Electro Medical Systems, Nyon, Switzerland)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iontophoresis
Description: Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED):

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: strengthening exercise
Study: NCT05529732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Mobile Application Patient Education for Patients with Thyroidectomy
Description: Its mobile application is prepared according to the Android Operating System and can be downloaded free of charge from the Google Play Store, it is an application that provides training and consultancy services for patients who have had thyroidectomy surgery.
Study: NCT04965428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear-focused Self-Compassion Therapy
Description: The Fear-focused Self-Compassion Therapy will be delivered as a group format. The intervention consists of eight group face-to-face sessions (60-90 minute for each session) and will be delivered by three trained therapists for eight weeks (sessions are weekly). Each intervention group involves 10 patients.
Study: NCT06330571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molar distalization by aligners with attachment
Description: 1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner.~4. Aligners will be fabricated on 3d printed models.~5. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~6. Patient will receive the following aligner after 2 weeks.~7. Follow up visits every 4weeks until 6 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Molar distalization by aligners with attachment
Description: 1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner.~4. Aligners will be fabricated on 3d printed models.~5. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~6. Patient will receive the following aligner after 2 weeks.~7. Follow up visits every 4weeks until 6 months.
Study: NCT05890300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of an occupational passive back-exoskeleton
Description: The experimental group will use an occupational passive back-exoskeleton (ShoulderX V3, Ottobock bionics) for a period of 24 weeks during working hours. The exoskeleton is designed to reduce the load of the lower back during manual materials handling. The first four weeks will serve as a familiarization period, where the workers will slowly progress in hours of exoskeleton-use, while they in the remaining twenty weeks will be free to use the exoskeleton as much as they like, with a minimum limit of 18 hours per week. The control group will carry on their normal work without any changes.
Study: NCT04731350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: strengthening exercise
Study: NCT05391945

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: Patient will be assessed by home Polysomnography(PSG), one night, Pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function.
Study: NCT06288542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group d
Description: this group will receive 1 mL/kg/h 5% Dextrose infusion, applied preoperatively during fasting until induction of anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group R
Description: this group will receive 1 mL/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia
Study: NCT05050422

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Trunk Impairment Scale (TIS), PedsQLTM Multidimensional Fatigue Scale (PedsQL-MFS), Pediatric Balance Scale (PBS)
Description: control/study group

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Trunk Impairment Scale (TIS), PedsQLTM Multidimensional Fatigue Scale (PedsQL-MFS), Pediatric Balance Scale (PBS)
Description: control/study group
Study: NCT05438134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP Group Intervention
Description: Nine 1.5 hour group sessions focusing on developing:~1. An understanding of stress physiology and the physiology of the relaxation response;~2. A regular practice of eliciting the relaxation response; and~3. Cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMART-3RP Group Intervention
Description: Nine 1.5 hour group sessions focusing on developing:~1. An understanding of stress physiology and the physiology of the relaxation response;~2. A regular practice of eliciting the relaxation response; and~3. Cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice.
Study: NCT04762303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedReviewRx
Description: During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
Study: NCT05247697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 7.5 MG Oral Tablet once daily at bedtime
Description: Mirtazapine 7,5 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet once daily at bedtime
Description: Matching placebo
Study: NCT05995093

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention